Beijing, March 29, 2021——InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that the Company will hold 2022 R&D Day themed on “Science Drives Innovation” in Beijing at 1:30 p.m. on April 20, 2021. InnoCare Management Team and leading PIs will share with the investors the latest development of the company’s research and development and other business development.
Investors who have interest can click the below link to submit participation information.
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, New Jersey and Boston.